Nano Labs Business Summary

Nano Labs Ltd (NA) operates as a fabless integrated circuit (IC) design company and product solution provider, primarily generating revenue through the sale of high-throughput computing (HTC) and high-performance computing (HPC) chips, alongside distributed computing and storage solutions. The company’s business is divided into two primary segments: Product (comprising approximately 84% of revenue) and Service (16%). Its technical portfolio includes the Cuckoo and Darkbird chip series, smart network interface cards (NICs), and vision computing chips designed for Web 3.0 infrastructure. Recently, the company has pivoted toward a "cryptocurrency reserve" model, aggressively accumulating digital assets like BNB and Bitcoin to strengthen its balance sheet. Nano Labs competes directly with firms such as Intchains Group (ICG), Canaan Inc. (CAN), and Bitmain, positioning itself as a niche, small-cap player focused on specialized ASIC applications and decentralized rendering in the highly volatile blockchain hardware market. The leadership team is anchored by Chairman and CEO Jianping (Jack) Kong and Vice Chairman Qifeng Sun, both of whom previously held senior executive roles at Canaan Inc., a pioneer in the Bitcoin mining hardware industry. This pedigree provides the company with deep institutional knowledge of the semiconductor and blockchain sectors. Key executives include CFO Bing Chen, who brings over 20 years of corporate management experience, and Bingbo Li, the CTO of the company’s primary operating subsidiary, Zhejiang Haowei. In July 2025, the company further bolstered its strategic direction by appointing Dr. Kailong Cai, a former partner at Jasper Crypto Fund and executive at Huobi Group, as CEO of its Nano bit subsidiary. The company is supported by a mix of institutional investors, including Susquehanna International Group and Heights Capital Management, while maintaining a board that features independent directors with backgrounds in digital finance and academic economics, such as Dr. Jiaming Zhu.